Clinical trials are the foundation of medical progress, driving the discovery of new treatments and improving patient outcomes. Highlands Oncology has been actively involved in clinical research for more than 26 years, conducting numerous studies in both oncology and hematology. Through these trials, new experimental medications—or innovative ways of using existing therapies—are compared to current standards of care. This process helps advance cancer treatment for patients locally and around the world. Each clinical trial follows strict eligibility criteria designed to ensure patient safety. Clinical trials typically progress through four phases of development:
Phase I: Determines safe dosage levels and evaluates safety
Phase II: Further assesses safety and begins to evaluate effectiveness
Phase III: Compares the new therapy to standard treatments
Phase IV: Studies the long-term safety and effectiveness of FDA-approved treatments
Highlands Oncology is proud to be the only community-based Phase I oncology clinical trial center in Arkansas, offering patients access to the newest and most innovative cancer therapies close to home.
Cancer research is constantly evolving, and new treatments emerge every year. Our Research Department ensures that Highlands Oncology remains at the forefront of medical innovation through continued participation in clinical trials. We are committed to providing every patient with as many treatment options as possible. Only you and your physician can decide if a clinical trial is right for you. To explore our currently enrolling studies, please visit our Clinical Trials page. For more information about clinical trials in general, visit clinicaltrials.gov.
J. Thaddeus Beck, Research Medical Director
Dr. Thad Beck expressed his desire to be involved in cancer clinical trials from the beginning of his career. His intellectual curiosity and desire to make a difference in patient outcomes have been a driving force in everything he does. As a founding member of Highlands Oncology, Dr. Beck sought to change the face of oncology in our community so that patients did not have to leave their hometown to receive cutting-edge cancer care.
Fortunately, Dr. Beck was persuaded to bring this energy and dream to Northwest Arkansas, where, as Medical Director he created from the ground up, one of the largest and most successful community-based clinical trial programs in the country. At any given time, he oversees over 140 active clinical trials, 30 providers, and over 50 clinical trials staff.
Even with this load, Dr. Beck still takes the time to sit with his patients, draw up a plan, and ensure that they understand and are prepared for the journey ahead.
He uses his exceptional expertise and years of experience to hand pick clinical trials he believes will be relevant and helpful for the patients in this community.
Frequently we have patients who will consider other large institutions or academic centers looking for an innovative clinical trial only to be redirected back home to Highlands where we have the exact same trial. This is a testament to the proficiency and expertise of Dr. Beck and his team.
Dr. Beck cares for his research team like he cares for his patients. He is always eager to answer questions about patients, oncology protocols, and treatments. He loves to teach those who enjoy learning to help them understand the significance of these trials in the future of oncology patient care.
Today, patients in Northwest Arkansas can participate in first-line clinical trials. Additionally, Highlands receives patients from around the world who travel here to participate in clinical trials where Phase I – III therapies are available.
“Such a pleasant experience. I would give all of them 100 stars.”
HIGHLANDS PATIENT
Contact Clinical trials
For questions or more information, please contact our Clinical Trials Team:
Paradigm/PHPE-07-002/Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
SOLID TUMORS
12/23/2025
Ovation.io/Ovation-23-001/Collection of Biological Specimens and Associated Health Information for Secondary Research
SOLID TUMORS
09/04/2025
UA-F/2406543345/Investigating the feasibility of monitoring tumor response to therapy using optical spectroscopy
SOLID TUMORS
01/01/2026
UA-F/2409564897/Gait and Body Composition as Clinical Biomarkers of Physical Function Decline in Individuals with Cancer
SOLID TUMORS
04/10/2025
Bristol-Myers Squibb/CA209-1573/Observational Time and Motion Study of Nivolumab Intravenous vs. Nivolumab in combination with hyaluronidase (Subcutaneous) in a Real-World Community Oncology Setting
SOLID TUMORS
08/28/2025
OncoC4/BiPAVE-001/Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 and VEGF, in Advanced Solid Tumors
SOLID TUMORS
06/26/2025
UA-F/Breast Biopsies/Investigating relevant biomarkers of breast cancer core biopsies to predict tumor response to chemotherapy using spectroscopy and non-linear imaging
BREAST
08/28/2025
Pfizer/6461008/AN INTERVENTIONAL 1B/2 OPEN-LABEL STUDY TO INVESTIGATE SAFETY AND EFFICACY OF PF-08634404 (SSGJ-707) MONOTHERAPY OR IN COMBINATION WITH OTHER AGENTS IN ADULT PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
OTHER
01/13/2026
Pfizer/C6461020/AN OPEN-LABEL PHASE 1B/2 STUDY TO INVESTIGATE PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN ADVANCED SOLID TUMORS
SOLID TUMORS
02/05/2026
Pfizer/C6461004/A PHASE 2/3 DOSE EXPANSION FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND STUDY OF PF 08634404 VS. ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER
LUNG - Small Cell Cancer (SCLC)
12/17/2025
Stemline/MEN2501-01/A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, in Participants with Ovarian Cancer
OTHER
11/12/2025
Pfizer/C6461003/AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED, STUDY EVALUATING PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN TREATMENT NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
COLORECTAL
02/10/2026
Pfizer/C6461001/AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
LUNG - Small Cell Cancer (SCLC)
12/23/2025
AstraZeneca/D9520C00001/A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Metastatic Prostate Cancer (SEACLIFF)
PROSTATE
09/17/2025
Eli Lilly/J6M-MC-JSGD/A Phase 3, Randomized, Double-blind, Placebo-controlled Study of LY4064809 Combined with a CDK4/6 inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation who received no prior treatment for Advanced Breast Cancer (PIKALO-2)
BREAST
11/11/2025
BioNTech/BNT327-05/
BREAST
11/12/2025
Abbvie/M25-713/A Phase 2/3 Study of Telisotuzumab Adizutecan Versus SOC After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713
LUNG - Non Small Cell Cancer (NSCLC)
12/03/2025
Pfizer/C5851005/A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
LUNG - Small Cell Cancer (SCLC)
01/30/2026
Exelixis/XB371-101/A Dose Escalation and Expansion Study of XB371 Administered in Participants with locally advanced or metastatic solid tumors
SOLID TUMORS
10/28/2025
Bristol-Myers Squibb/CA240-0030/A Randomized Phase 2-3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
OTHER
09/25/2025
Bristol-Myers Squibb/CA240-0029/A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion
LUNG - Non Small Cell Cancer (NSCLC)
09/08/2025
Pfizer/C4551002/An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigators Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy Study
BREAST
08/18/2025
Novartis/CJSB462B12201/A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)
PROSTATE
02/19/2026
Pfizer/C2321008/A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
PROSTATE
09/22/2025
Merck/V940-012/A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940, also called mRNA-4157, Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma. Nickname: INTerpath-012
MELANOMA
06/13/2025
Henlius USA Inc./HLX43-NSCLC201/An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
LUNG - Non Small Cell Cancer (NSCLC)
09/03/2025
Eli Lilly/J3M-MC-JZQH/A Phase 3, Multi-center, Double-blind, 2-part Study in Participants with KRAS G12C-Mutant, Non-Small Cell Lung Cancer Comparing the Efficacy and Safety of Olomorasib in Combination with Standard of Care to Placebo in Combination with Standard of Care as Adjuvant Treatment after Platinum-based Chemotherapy
LUNG - Non Small Cell Cancer (NSCLC)
06/19/2025
Novartis/CAAA601A62301/A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3)
SOLID TUMORS
05/22/2025
Pfizer/C4391024/AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE
BREAST
02/27/2025
Johnson&Johnson/61186372COR3002/A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
COLORECTAL
01/28/2026
ImmunityBio/ResQ201A-NSCLC/RANDOMIZED, OPEN-LABEL, PHASE 3 CLINICAL TRIAL OF N-803 PLUS TISLELIZUMAB AND DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE ACQUIRED RESISTANCE TO IMMUNE CHECKPOINT INHIBITOR THERAPY
LUNG - Non Small Cell Cancer (NSCLC)
09/26/2025
AstraZeneca/D702BC00001/A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
LUNG - Non Small Cell Cancer (NSCLC)
12/19/2024
Johnson & Johnson/61186372COR3001/A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
COLORECTAL
01/29/2026
Stemline/MEN2312-01/A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer, 285057
BREAST
11/26/2024
Pfizer/C2321003/A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
PROSTATE
03/14/2025
NRG Oncology/NRG-GY036/A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
OTHER
10/14/2025
Hoffman-La Roche/BO45230/A Randomized Phase II, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Placebo Plus Nivolumab as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Urothelial Carcinoma
OTHER
12/30/2025
Stemline/STML-ELA-0422/Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
BREAST
12/09/2024
SWOG/S2312/A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature
PROSTATE
01/09/2025
Pfizer/C5421001/A PHASE 1 OPEN-LABEL STUDY OF PF-07934040 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS
SOLID TUMORS
03/07/2025
AstraZeneca/D516KC00001/A Phase III, Open Label, Sponsor-Blind, Randomized Study of Dato DXd With or Without Osimertinib Versus Platinum-Based Doublet Chemotherapy for Patients with EGFR-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)
LUNG - Non Small Cell Cancer (NSCLC)
09/27/2024
AstraZeneca/D7632C00001/Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC greater than/equal to 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)
LUNG - Non Small Cell Cancer (NSCLC)
11/20/2024
SWOG/S2308/Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
OTHER
09/30/2025
Merck/MK2870-019/A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stage II to IIIB (N2) NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery
LUNG - Non Small Cell Cancer (NSCLC)
11/08/2024
Personalis/01-PS-001/Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
BREAST
01/01/2026
Daiichi Sankyo/DS7300-188/A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physicians Choice (TPC) in Subjects with Relapsed Small Cell Lung Cancer (SCLC) (IDeate-2)
LUNG - Small Cell Cancer (SCLC)
12/23/2025
AstraZeneca / D9723C00001 / A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
PROSTATE
12/15/2023
Eli Lilly/J3M-MC-JZQB/A Global Pivotal Study in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of Pembrolizumab and LY3537982 vs Pembrolizumab and Placebo in those with PD-L1 ≥ 50% or Pembrolizumab, Pemetrexed, Platinum Chemotherapy and LY3537982 vs Pembrolizumab, Pemetrexed, Platinum Chemotherapy and Placebo regardless of PD-L1 Expression
LUNG - Non Small Cell Cancer (NSCLC)
02/27/2025
AstraZeneca/D7630C00001/A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
BREAST
06/04/2024
ECOG/EA5221/A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer - The ACHIEVE Study
LUNG - Non Small Cell Cancer (NSCLC)
10/18/2024
Alliance/A032103/MODERN: AN INTEGRATED PHASE 2/3 AND PHASE 3 TRIAL OF MRD-BASED OPTIMIZATION OF ADJUVANT THERAPY IN UROTHELIAL CANCER
OTHER
06/11/2024
UAMS/275695/A Phase II Clinical Trial of Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence (Candin)
HEAD/NECK
07/22/2024
AstraZeneca/D8535C00001/CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
BREAST
01/18/2024
Novartis/CAAA617D12302/An International, Prospective, Open-label, Multi-center,Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan(AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
PROSTATE
03/07/2025
Lantern Pharma / LTRN184-1AST23-1 / A PHASE 1A DOSE ESCALATION STUDY OF LP-184 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
SOLID TUMORS
12/28/2023
SWOG/S2212/Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
BREAST
09/24/2025
Alliance/A012103/optimICE-pCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
BREAST
08/15/2023
AbbVie/M24-108/A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma
MULTIPLE MYELOMA
12/10/2024
SWOG/S2114/A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
OTHER
07/01/2025
AstraZeneca D926XC00001 – A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
BREAST
02/15/2023
Stemline STML-ELA-0322 – ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)
BREAST
07/26/2023
Stemline STML-ELA-0222 – A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
BREAST
07/27/2023
SWOG/S2209/A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of Intermediate Fit Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single Agent Maintenance
MULTIPLE MYELOMA
01/15/2025
Seattle Genetics/SGNB6A-001/A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
SOLID TUMORS
06/13/2025
AstraZeneca D926NC00001 Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)
LUNG - Non Small Cell Cancer (NSCLC)
05/25/2023
Pfizer C4901001: A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
SOLID TUMORS
11/11/2022
Shanghai Henlius Biotech HLX10-005-SCLC301-E: A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
LUNG - Small Cell Cancer (SCLC)
12/12/2022
Revolution Medicines RMC-6291-001: Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
LUNG - Non Small Cell Cancer (NSCLC)
10/24/2022
Ascentage Pharma APG-5918XG101: A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies
OTHER
10/13/2022
Pfizer C4761001- A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS
MELANOMA
05/26/2022
Daiichi Sankyo DS7300-127: A Phase 2, Multicenter, Randomized, Open-label Study of DS-7300a, a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
LUNG
01/11/2023
Freenome FRNM-008: The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
OTHER
12/27/2022
Eli Lilly I3Y-MC-JPEF: A Phase 3: Randomized, Double Blind: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Advanced or Metastatic Breast, HR+, HER2-, following progression on a CDK 4/6 Inhibitor and Endocrine Therapy.
BREAST
01/10/2022
Novartis CLEE011A2412B: A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study
BREAST
07/07/2022
AstraZeneca D967RC00001: A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
BREAST
01/26/2023
Merck MK1026-003: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
OTHER
02/02/2023
AstraZeneca D8532C00001 (SERENA-4): A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.
BREAST
12/06/2021
Mirati Therapeutics Inc. 849-007: Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7.
LUNG - Non Small Cell Cancer (NSCLC)
11/02/2021
Seagen Inc., SGN35-033: A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment
MELANOMA
10/17/2022
OncoC4 ONC-392-001: Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
